الصفحة الرئيسية>>Signaling Pathways>> GPCR/G protein>> CRFR>>CP 316311

CP 316311

رقم الكتالوجGC31043

CP 316311 هو مضاد لمستقبل CRF1 قوي وانتقائي بقيمة IC50 تبلغ 6.8 نانومتر

Products are for research use only. Not for human use. We do not sell to patients.

CP 316311 التركيب الكيميائي

Cas No.: 175139-41-0

الحجم السعر المخزون الكميّة
1mg
534٫00
متوفر
5mg
1057٫00
متوفر
10mg
1801٫00
متوفر
20mg
3171٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

CP 316311 is a potent and selective CRF1 receptor antagonist with an IC50 value of 6.8 nM.

CP 316311 fully antagonizes CRF-stimulated adenylate cyclase activity in rat cortex and at human CRF1 receptors endogenously expressed in IMR32 cells with apparent Ki values of 7.6 and 8.5 nM, respectively[1].

CP 316311 (3.2 mg/kg) inhibits 125I-oCRF binding by >80% in rats. CP 316311 significantly attenuates activation of the hypothalamic-pituitary-adrenal (HPA) axis, with an MED value of 10 mg/kg, p.o. CP 316311 blocks the effects of both the exogenous and endogenous CRF in the CNS. CP 316311 blocks the effects induced by the exogeneous or endogeneous CRF in the brain in rat models[1].

[1]. Chen YL, et al. Synthesis and SAR of 2-aryloxy-4-alkoxy-pyridines as potent orally active corticotropin-releasing factor 1 receptor antagonists. J Med Chem. 2008 Mar 13;51(5):1377-84.

مراجعات

Review for CP 316311

Average Rating: 5 ★★★★★ (Based on Reviews and 13 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for CP 316311

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.